To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

After successful screening of liver cirrhosis patients attending ILBS OPD for signs of parkinsonism ( tremor, rigidity or bradykinesia, any 2 of 3). Diagnosis of hepatic/cirrhosis related parkinsonism will be made. Patients will be randomized into Bromocriptine and Placebo. Patients will be followed up every month in OPD (Out Patient Department), ILBS (Institute of liver & Biliary Sciences) for 3 months. Detailed neurological examination will be done at each visit & UPDRS (Unified Parkinson's Disease Rating Scale ) score will be calculated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: Bromocriptine; Lactulose; Rifaximin

Criteria

Inclusion Criteria:

• Patients with cirrhosis of liver with signs of parkinsonisms

• Patients consented for the study protocol by signing the informed consent.

Exclusion Criteria:

• Age < 18 years.

• Patient s with HCC (Hepatocellular Carcinoma).

• Patients diagnosed as Wilsons disease.

• Patient who withdrew or non complaint to the study protocol.

• ALF (Acute Liver failure)

• Classical Parkinsonism

• Atypical Parkinsonism

• Pregnancy

• Hypotension

• Uncontrolled hypertension

• CAD

• Psychiatric illness

• Acute episode of Hepatic encephlopathy